Publication at Third Faculty of Medicine |
2009
Abstract
The most frequently used estrogenic component in oral contraceptives is ethinylestradiol. Although, its both efficacy and safety have been demonstrated in many clinical trials, there are several aspects, where it substantially differs from endogenic 17-beta-estradiol.
The newly developed estradiol valerate is being introduced into the clinical praxis in a form of fixed combination with dienogest in order to improve the safety profile of current oral contraceptive preparations, particularly regarding the risk of venous thromboembolism.